Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 27;29(8):2099–2109. doi: 10.1038/s41591-023-02452-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023, corrected publication 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 6 — Tumor regression in a 36-year-old male with epithelioid malignant peritoneal mesothelioma treated at dose level 1 after checkpoint inhibitor failure. a, Representative MRI images at baseline and CT scan images 6 months post gavo-cel infusion showing complete tumor regression of lesion abutting the left kidney (lesion 1) and reduction in size of the tumor in the peritoneal reflection of the rectum (lesion 2). b–c, Circulating surrogate biomarkers of tumor response. b, Decrease in serum SMRP and c, MPF levels following gavo-cel infusion. Tumor regression in a 70-year-old female with platinum refractory high grade serous ovarian cancer treated at dose level 1. d, Representative CT scan images show regression in target lesion size of mediastinal lymph node (lesion 1) and abdominal retro-caval lymph node (lesion 2) at 1- and 3- months after gavo-cel infusion and maintained up to 6 months post treatment. The measurements denote the size of the target lesions Source Data.